Trial · NCT00632853

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

NCT00632853, Phase 3, Completed, Alliance for Clinical Trials in Oncology; results first posted 2023-06-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide. Trials, record NCT00632853. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00632853

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
NCT number: NCT00632853
Status: Completed
Phases: Phase 3
Enrollment: 731 participants, actual
Lead sponsor: Alliance for Clinical Trials in Oncology
Conditions: Lung Cancer
Interventions: Standard Radiation Dose Therapy, cisplatin, etoposide, High Radiation Dose Therapy, carboplatin
First posted: 2008-03-11
Last updated: 2026-09-10
Results first posted: 2023-06-12

Source ClinicalTrials.gov

Registered outcomes10

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Survival Time	11.25 years	Overall survival time is defined as the time between a patient's registration and death or end of survival follow up.
Secondary	Complete and Partial Response Rates	11.25 years
Secondary	Failure-free>> Survival	Up to 5 years
Secondary	To Compare Rates of Local Relapse, Distant Metastases and Brain Metastases With These > Regimens.	5 years
Secondary	To Compare Patients' Quality of Life Between These Treatment Regimens in Terms of Their > Physical Symptoms, Physical Functioning and Psychological State.	5 years
Secondary	To Describe the Patterns of Use of Thoracic Intensity Modulated Radiation Therapy (IMRT) in Patients With Limited Stage Small Cell Lung Cancer.	5 years
Secondary	To Examine Blood-based Biomarkers of Response and Resistance to Cisplatin (or Carboplatin) and Etoposide.	5 years
Secondary	To Evaluate the Correspondence Between Increases in Plasma ProGRP Concentrations and Disease Progression/Recurrence	5 years
Secondary	To Evaluate the Potential for Plasma ProGRP Concentrations at Baseline, After Each Cycle of > Chemotherapy and at First Evaluation Following Completion of Chemotherapy to Predict PFS and OS.	5 years
Secondary	To Evaluate the Correspondence Between Longitudinal Decreases in Plasma ProGRP Concentrations and Clinical Response.	5 years

Source ClinicalTrials.gov

Outcomes10

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Survival Time	11.25 years	All registered patients were included in this analysis.	Months	MEDIAN
SECONDARY	Complete and Partial Response Rates	11.25 years
SECONDARY	Failure-free >> Survival	Up to 5 years
SECONDARY	To Compare Rates of Local Relapse, Distant Metastases and Brain Metastases With These > Regimens.	5 years
SECONDARY	To Compare Patients' Quality of Life Between These Treatment Regimens in Terms of Their > Physical Symptoms, Physical Functioning and Psychological State.	5 years
SECONDARY	To Describe the Patterns of Use of Thoracic Intensity Modulated Radiation Therapy (IMRT) in Patients With Limited Stage Small Cell Lung Cancer.	5 years
SECONDARY	To Examine Blood-based Biomarkers of Response and Resistance to Cisplatin (or Carboplatin) and Etoposide.	5 years
SECONDARY	To Evaluate the Correspondence Between Increases in Plasma ProGRP Concentrations and Disease Progression/Recurrence	5 years
SECONDARY	To Evaluate the Potential for Plasma ProGRP Concentrations at Baseline, After Each Cycle of > Chemotherapy and at First Evaluation Following Completion of Chemotherapy to Predict PFS and OS.	5 years
SECONDARY	To Evaluate the Correspondence Between Longitudinal Decreases in Plasma ProGRP Concentrations and Clinical Response.	5 years

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Overall Survival Time	Arm A	28.7	95% Confidence Interval 26.2 to 35.5	Months
Overall Survival Time	Arm B	30.5	95% Confidence Interval 24.4 to 39.6	Months
Overall Survival Time	Arm C	32.3	95% Confidence Interval 21.1 to 44.8	Months

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Arm A	313
Overall Study	STARTED	Arm B	325
Overall Study	STARTED	Arm C	93
Overall Study	COMPLETED	Arm A	313
Overall Study	COMPLETED	Arm B	325
Overall Study	COMPLETED	Arm C	93
Overall Study	NOT COMPLETED	Arm A	0
Overall Study	NOT COMPLETED	Arm B	0
Overall Study	NOT COMPLETED	Arm C	0

Source ClinicalTrials.gov

Adverse events789

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Blood disorder	Blood and lymphatic system disorders	Arm A	7	313	10
other	Blood disorder	Blood and lymphatic system disorders	Arm B	7	325	12
other	Blood disorder	Blood and lymphatic system disorders	Arm C	1	93	1
other	Febrile neutropenia	Blood and lymphatic system disorders	Arm A	41	313	51
other	Febrile neutropenia	Blood and lymphatic system disorders	Arm B	39	325	44
other	Febrile neutropenia	Blood and lymphatic system disorders	Arm C	11	93	13
other	Hemoglobin decreased	Blood and lymphatic system disorders	Arm A	246	313	681
other	Hemoglobin decreased	Blood and lymphatic system disorders	Arm B	247	325	660
other	Hemoglobin decreased	Blood and lymphatic system disorders	Arm C	73	93	206
other	Hemolysis	Blood and lymphatic system disorders	Arm A	2	313	2

1 to 10 of 789Source ClinicalTrials.gov

See all 789 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Arm A	206	313
Total, all-cause mortality	Arm B	220	325
Total, all-cause mortality	Arm C	73	93
Total, other adverse events	Arm A	292	313
Total, other adverse events	Arm B	296	325
Total, other adverse events	Arm C	87	93
Total, serious adverse events	Arm A	4	313
Total, serious adverse events	Arm B	11	325
Total, serious adverse events	Arm C	4	93

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
36623230	DERIVED	PubMed
39446327	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA031946	Cancer and Leukemia Group B	BERTAGNOLLI, MONICA M	BRIGHAM AND WOMEN'S HOSPITAL	NATIONAL CANCER INSTITUTE	1985 to 2013

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00632853

GET https://conductscience.org/api/trials/v1/NCT00632853/events?page=2

API reference For AI assistants